Scott James received his MD and PhD from the University of Washington in Seattle where he studied aspects of chimeric antigen receptor-mediated T cell targeting related to target antigen topology and tissue expression. He subsequently completed internal medicine residency at University of Washington and joined the MSKCC hematology/oncology program. Upon completing his fellowship at MSKCC, he joined the Bone Marrow Transplantation Service as faculty member.
Chimeric antigen receptor-modified T cells have demonstrated clinical successes in B cell malignancies and are currently being evaluated in other malignancies targeting novel antigens. I am interested in synthetic biology approaches to modify T cell behavior and function with the goal of improving the clinical efficacy and tissue selectivity of adoptive cellular immunotherapy. I additionally am interested in the application of synthetic biology approaches, including chimeric antigen receptors, to improve graft vs. leukemia/lymphoma responses while decreasing graft vs. host responses in the transplant setting.
- Parker Institute for Cancer Immunotherapy - Parker Bridge Scholar (2017-2020)
- Amy Strelzer Manasevit Research Program Award (2017-2020)
- ASCO Young Investigator Award (2016-2017)
- T32 institutional training grant (Academic year 2015 – 2016)
- University of Washington School of Medicine | Seattle, WA
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Scott James discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.